Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bicarbonate buffered solution is an intravenous balanced crystalloid fluid designed for intravascular volume maintenance and resuscitation, particularly in major surgical settings such as abdominal surgery and liver transplantation. Unlike traditional balanced solutions like Hartmann's (lactate-buffered) or Plasma-Lyte (acetate/gluconate-buffered), this formulation utilizes bicarbonate (HCO3−) as its primary buffering agent to more closely mimic physiological acid-base balance. It typically contains a chloride concentration of approximately 110 mmol/L, which is similar to Hartmann's solution but lower than normal saline. Clinical research, notably led by Professor Rinaldo Bellomo at the Austin Hospital in Melbourne, has focused on its physiochemical effects, specifically its ability to maintain standard base excess and prevent hyperchloremic acidosis compared to other crystalloids in perioperative environments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bicarbonate buffered solution.